United States

Reimbursed Care Access

In the United States, a limited medical framework exists for ketamine-derived treatments (FDA‑approved esketamine/SPRAVATO with REMS requirements and wide off‑label IV/IM ketamine use in private clinics), while classical psychedelics such as psilocybin and MDMA remain unapproved at the federal level but are the focus of advanced clinical trials and regulatory submissions. Most other compounds (DMT, 5‑MeO‑DMT, ibogaine, ayahuasca, mescaline, 2C‑X) are federally scheduled or controlled and have no authorized medical use outside approved research; access therefore is mainly via clinical trials or state/local policy experiments. [https://spravatorems.com|SPRAVATO REMS] [https://maps.org/2023/12/13/maps-celebrates-submission-of-new-drug-application-to-fda-for-mdma-assisted-therapy-for-ptsd/|MAPS NDA announcement] [https://www.forbes.com/sites/ajherrington/2025/08/23/dea-forwards-psilocybin-rescheduling-petition-to-hhs-for-review/|Forbes on psilocybin rescheduling action]